Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study

Circulation

Volumn 111, Issue 24, 2005, Pages 3274-3280

  Humpl, Tilman ^a   Reyes, Janette T ^a   Holtby, Helen ^a   Stephens, Derek ^a   Adatia, Ian ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Heart defects, congenital; Hypertension, pulmonary; Pediatrics; Pharmacology; Phosphodiesterase inhibitors

Indexed keywords

PROGESTERONE; SILDENAFIL;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MENARCHE; MENSTRUATION DISORDER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TIME; WALKING;

ADOLESCENT; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; EXERCISE TEST; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; PILOT PROJECTS; PIPERAZINES; PULMONARY ARTERY; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS; WALKING;

EID: 21044449937     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.473371     Document Type: Article

References (29)

1. Higenbottam T, Wells F, Wheeldon D, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1:1046-1047.
2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
3. Fuster V, Steele PM, Edwards WD, Gersch BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation. 1984;70:580-587.
4. Rubin LJ, Badesch DB, Barst RJ, Galié N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346: 896-903.
5. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358: 1119-1123.
6. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR, STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169: 441-447.
7. Ivy DD, Parker D, Doran A, Kinsella JP, Abman SH. Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. Am J Cardiol. 2003;92:886-890.
8. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension. Chest. 1996;109:1545-1549.
9. Olschewski H, Simonneau G, Galié N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Spech R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manies A, Kiely DG, Ewart R, Meyer A, Corris PA, Delacroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347: 322-329.
10. Mikhail G, Gibbs JSR, Richardson M, Wright G, Khaghani A, Banner N, Yacoub M. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J. 1997;18: 1499-1504.
11. Higenbottam T, Stenmark K, Simonneau G. Treatments for severe pulmonary hypertension. Lancet. 1999;353:338-339.
12. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428.
13. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation. 2002; 105: 2398-2403.
14. Ghofrani HA, Wiederman R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895-900.
15. Michelakis ED, Tymchak W, Noga M, Webster L, Wu X-C, Lien D, Wang S-H, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108:2066-2069.
16. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003;239:239-244.
17. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
18. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliott CG, Fishman AP, Goldring RM, Groves BM, Kernis JT, Koerner SK, Levy PS, Pietra GS, Reid LM, Rich S, Vreim CE, Williams GW, Wu M. The acute administration of vasodilators in primary pulmonary hypertension. Am Rev Respir Dis. 1989;140:1623-1630.
19. Miyamoto S, Nagaya N, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension comparison with cardiopulmonary testing. Am J Respir Crit Care Med. 2000;181:487-492.
20. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PLM. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372-382.
21. Barst RJ. Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension. Chest. 1986;89: 497-503.
22. Houde C, Bohn DJ, Freedom R, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension as judged by responsiveness to vasodilators. Br Heart J. 1993;70:461-468.
23. Wagenvoort CA, Wagenvoort N. Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol. 1974;11: 123-130.
24. Edwards JE. Pathology of chronic pulmonary hypertension. Pathol Ann. 1974;9:1-25.
25. Ghofrani H, Wiedeman R, Rose F, Olschewski H, Schermuly RT, Weissman N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136:515-522.
26. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158-154.
27. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, Böhm M, Sybrecht G. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-1222.
28. Mitani Y, Zaidi SHE, Dufourcq P, Thompson K, Rabinovitch M. Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AML1B nuclear partitioning. FASEB J. 2000;14:805-814.
29. Languepin J, Scheinmann P, Mahut B, Bourgeois ML, Jaubert F, Brunelle F, Sidi D, Blic JD. Bronchial casts in children with cardiopathies: the role of pulmonary lymphatic abnormalities. Pediatr Pulmonol. 1999;28: 329-336.